Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms
DarioHealth's next earnings callDariohealth (NASDAQ:DRIO) Q3 2026 Earnings Call · Nov 12, 2026 at 8:30 AM ESTRegister
The original release is unavailable here.
Earlier from DarioHealth
- Dario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members
- Dario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio
- DarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date
- DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
- DarioHealth Reports Third Quarter 2025 Financial and Operating Results
Later from DarioHealth
- Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
- Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health
- DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
- DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling
Follow DarioHealth into a list and get an email when it puts out news.
Follow DarioHealth